Trial Profile
Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 10 Aug 2016 Status changed from recruiting to completed.
- 14 May 2009 New trial record